Arcus Biosciences (RCUS) has wrapped up FY 2025 with fourth quarter revenue of US$33 million and a basic EPS loss of US$0.89, alongside a net loss of US$106 million. This sets a clear backdrop of solid top line contributions paired with continued negative earnings. The company has reported quarterly revenue of US$26 million in Q4 2024, US$28 million in Q1 2025, US$160 million in Q2 2025, US$26 million in Q3 2025 and US$33 million in Q4 2025, while EPS has remained in loss territory across these periods. This keeps the focus on how efficiently that revenue is being translated into potential future profitability. For investors, the key consideration this quarter is how these revenue figures align with the ongoing losses and what that may indicate for margins as the pipeline progresses.

See our full analysis for Arcus Biosciences.

With the latest numbers on the table, the next step is to see how this earnings profile compares with the key narratives around growth potential, risks and the possible path to improving margins that investors have been discussing over the past year.

US$353 million TTM loss keeps profitability out of reach

• On a trailing 12 month basis to Q4 2025, Arcus reported total revenue of US$247 million and a net loss of US$353 million, so losses are larger than the full year revenue base.
• Bears point to this scale of loss as a sign that clinical spending could weigh on the business for a long time, and the history of losses increasing at about 25.5% a year fits that concern.
  • The latest trailing 12 month basic EPS loss of US$3.29, against a current share price of US$19.54, underlines that the market is valuing the company entirely on future potential rather than current earnings.
  • Bears also highlight that forecasts in the data do not show profitability over the next three years, which is consistent with the current pattern of quarterly net losses ranging from US$94 million to US$135 million outside the Q2 2025 break-even quarter.

Arcus’ recent record of rising losses and no near term profitability is exactly what skeptics focus on, so if you lean cautious, it may help to read how they build that case in the 🐻 Arcus Biosciences Bear Case.

Pipelines in Phase I to III vs widening losses

• Across 2024 and 2025, Arcus reported up to 16 products in Phase I, 7 in Phase II and 5 in Phase III, alongside quarterly net losses that reached US$135 million in Q3 2025 and US$106 million in Q4 2025.
• Bullish investors argue that this breadth of late stage programs can justify the heavy losses today, and the data on trial count is what they often point to.
  • For example, Q3 2024 showed 16 Phase I and 4 Phase III products, while by Q3 2025 the company still had 8 Phase I and 5 Phase III programs, suggesting continued investment across early and late stages.
  • Bulls see this as consistent with a growth story supported by forecast revenue growth of around 29.8% a year in the dataset, even though the current trailing 12 month loss of US$353 million shows that payoff is not yet visible in earnings.

If you want to see how supporters connect this pipeline depth to future outcomes and valuation, the detailed bullish case on Arcus is worth a look at 🐂 Arcus Biosciences Bull Case.

P/S of 9.9x and DCF fair value tension

• The stock is trading on a P/S of 9.9x versus 12.5x for the broader US biotech group and 9.3x for direct peers, while the supplied DCF fair value of US$130.41 sits far above the current price of US$19.54.
• What stands out here is how bullish views lean on these valuation signals, while the loss profile in the results gives a very different message.
  • On one hand, a trailing 12 month revenue base of US$247 million and a P/S below the broader industry line up with the idea that the shares look inexpensive on sales compared with many biotech names.
  • On the other hand, the same trailing period shows a net loss of US$353 million and a basic EPS loss of US$3.29, which sits awkwardly beside a DCF fair value that is a multiple of the current share price and requires investors to be comfortable with extended loss making.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arcus Biosciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After all this, do you feel the story leans more bullish or cautious? Take a moment to review the full picture, then weigh the balance of risks and upsides through 2 key rewards and 3 important warning signs.

See What Else Is Out There

Arcus is carrying a trailing 12 month net loss of US$353 million on US$247 million of revenue, with ongoing quarterly losses and no near term profitability in the provided forecasts.

If you are uneasy about that level of loss and the reliance on future potential, you may wish to shift your focus toward companies in the 80 resilient stocks with low risk scores that pair more modest risk profiles with fundamentals you can assess today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.